Nuclear factor kappa B: A marker of chemotherapy for human stage IV gastric carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 30

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

240

HTML

2303

Figures (1-3)

106

Tables (1-1)

131

Sum=2780

Aug 14, 2008 (publication date) through Apr 24, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Gastric Cancer

World J Gastroenterol. Aug 14, 2008; 14(30): 4739-4744
Published online Aug 14, 2008. doi: 10.3748/wjg.14.4739

Table 1 Data obtained from patients in the two treatment groups

	FOLOFOX group (n = 44)	PLF group (n = 16)	P
Sex (male/female)	29/15	11/5	0.547
Age (yr)	51.51 ± 13.10	49.06 ± 12.36	0.521
General state of health ECOG patients
0 score	1	1	0.721
1 score	32	12
2 scores	11	4
Primary location
Cardiac orifice	11	2	0.431
Stomach	19	12
Gastric remnant	4	2
Accumulative organs
1	3	1	0.1642
2	23	3
3	16	8
> 3	2	4
Pathologic classification
Moderately-differentiated	9	4	0.691
Poorly-differentiated	33	12	0.336
Undifferentiated	2	0	0.132

Citation: Ye S, Long YM, Rong J, Xie WR. Nuclear factor kappa B: A marker of chemotherapy for human stage IV gastric carcinoma. World J Gastroenterol 2008; 14(30): 4739-4744
URL: https://www.wjgnet.com/1007-9327/full/v14/i30/4739.htm
DOI: https://dx.doi.org/10.3748/wjg.14.4739